Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.56 and traded as low as $0.46. Northwest Biotherapeutics shares last traded at $0.47, with a volume of 2,516,778 shares trading hands.
Northwest Biotherapeutics Stock Down 5.7 %
The company has a market capitalization of $575.90 million, a P/E ratio of -6.71 and a beta of -0.63. The business has a 50 day simple moving average of $0.47 and a 200-day simple moving average of $0.56.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last issued its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.02) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Featured Articles
- Five stocks we like better than Northwest Biotherapeutics
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- How to invest in blue chip stocks
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- The Most Important Warren Buffett Stock for Investors: His Own
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
